The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
about
Vascular disrupting agent drug classes differ in effects on the cytoskeletonRelationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarizationLabeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responsesDirect Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.Vascular-targeted agents for the treatment of angiosarcoma.STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression.
P2860
Q28481498-E2B12C61-B2B7-489A-A21D-0E01B686F1E0Q33198390-BDEB163B-8595-46E1-A1BA-44990190136AQ33773787-3F6A65D7-F267-4073-B443-A017A301C1A6Q34105372-C35C6EB9-9C62-437E-8E44-CE8EC088F9B3Q34122191-4FBD722F-65E3-4F44-8DDE-3B28A08CE50DQ35115922-187CE006-7A63-4AE7-83B1-C243DE4651F2Q35634752-931BDEFB-87F9-4E62-BD8B-B4AC89977725Q36229527-7C06A77B-FCAC-4081-9FA1-3E47F050AA68Q36641876-5EC73CA9-CC60-4C17-A316-24553F314F80Q36747400-2C27518A-359D-4B32-A548-2F4630FFB419Q36972860-9E75AB24-D365-4E52-96C0-7310048B3077Q37269347-578BA5E5-337B-46C1-A0C6-1AF5B1CA4D7FQ37668618-094D2EF3-A2CF-4DE6-82B1-8FA7332575AAQ38685276-10CF2485-182C-4C52-9436-F1A02286D5D7Q39029184-13FD8DDE-4CBF-4D70-958E-C9DAEEB09949Q39061298-64B7CCE7-5502-4B95-A3B4-1F5DDE589530Q39708605-889146D0-54F4-49AC-97BE-6520816BB851Q40256708-6E98C02B-96E3-4DF8-9DF0-F14C97F7EA11Q42906483-F72E7A1A-738B-462B-B77E-F1B72D0025B8Q46142906-B613F246-304C-4BC7-9EFB-846A587DFEF0
P2860
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
The antitumour activity of 5,6 ...... TNF receptor-1 knockout mice.
@en
type
label
The antitumour activity of 5,6 ...... TNF receptor-1 knockout mice.
@en
prefLabel
The antitumour activity of 5,6 ...... TNF receptor-1 knockout mice.
@en
P2093
P2860
P356
P1476
The antitumour activity of 5,6 ...... TNF receptor-1 knockout mice.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600479
P407
P577
2002-08-01T00:00:00Z
P5875
P6179
1021994551